Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

BACKGROUND: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Trněný, Marek, Avigdor, Abraham, McKinney, Matthew S., Paneesha, Shankara, Wahlin, Björn E., Hrom, John S., Cunningham, David, Morley, Nicholas, Canales, Miguel, Bastos-Oreiro, Mariana, Belada, David, Devizzi, Liliana, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Jiang, Ping, Lynch, Ryan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469382/
https://www.ncbi.nlm.nih.gov/pubmed/37662520
http://dx.doi.org/10.1016/j.eclinm.2023.102130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469382/
https://www.ncbi.nlm.nih.gov/pubmed/37662520
http://dx.doi.org/10.1016/j.eclinm.2023.102130

Ejemplares similares